溶瘤腺病毒SG611联合顺铂对肝癌细胞HepG2的协同杀伤作用及其机制

doi:10.3877/cma.j.issn.2095-3232.2015.02.014

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (02) : 119 -124. doi: 10.3877/cma.j.issn.2095-3232.2015.02.014

所属专题：文献；

基础研究

溶瘤腺病毒SG611联合顺铂对肝癌细胞HepG2的协同杀伤作用及其机制

胡朝霞¹, 台艳², 刘炜², 邱东波³, 张琪⁴^,^†(

)

^1. 510630　广州，中山大学附属第三医院感染科；510630　广州，广东省肝脏疾病研究重点实验室
^2. 510630　广州，广东省肝脏疾病研究重点实验室
^3. 510630　广州，中山大学附属第三医院细胞与基因治疗转化医学研究中心
^4. 510630　广州，中山大学附属第三医院细胞与基因治疗转化医学研究中心；510630　广州，广东省肝脏疾病研究重点实验室

收稿日期:2015-02-03 出版日期:2015-04-10
通信作者: 张琪
基金资助:
十二五重大科技专项(2012ZX10002016-023，2012ZX10002017-005，2012ZX10002010-001-007); 国家自然科学基金(81170452，81370555); 广东省自然科学基金(S20120011190); 广东省科技计划项目(2012B061500005)

Synergistic cytotoxic effects and mechanism of oncolytic adenovirus SG611 combined with cisplatin on hepatocellular carcinoma HepG2 cells

Zhaoxia Hu¹, Yan Tai², Wei Liu², Dongbo Qiu³, Qi Zhang⁴^,^†()

^1. Department of Infectious Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China; Guangdong Provincial Key Laboratory of Liver Disease, Guangzhou 510630, China
^2. Guangdong Provincial Key Laboratory of Liver Disease, Guangzhou 510630, China
^3. Cell and Gene Therapy Translational Medicine Research Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
^4. Guangdong Provincial Key Laboratory of Liver Disease, Guangzhou 510630, China; Cell and Gene Therapy Translational Medicine Research Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

Received:2015-02-03 Published:2015-04-10
Corresponding author: Qi Zhang
About author:
Corresponding author: Zhang Qi, Email:zhangq27@mail.sysu.edu.cn

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

胡朝霞, 台艳, 刘炜, 邱东波, 张琪. 溶瘤腺病毒SG611联合顺铂对肝癌细胞HepG2的协同杀伤作用及其机制[J/OL]. 中华肝脏外科手术学电子杂志, 2015, 04(02): 119-124.

Zhaoxia Hu, Yan Tai, Wei Liu, Dongbo Qiu, Qi Zhang. Synergistic cytotoxic effects and mechanism of oncolytic adenovirus SG611 combined with cisplatin on hepatocellular carcinoma HepG2 cells[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(02): 119-124.

目的

探讨溶瘤腺病毒SG611联合顺铂（DDP）对肝细胞癌（肝癌）细胞HepG2的协同杀伤作用及其作用机制。

方法

利用携带GFP的腺病毒载体SG611感染人肝癌细胞HepG2，流式细胞术检测SG611感染效率，CCK-8实验检测SG611联合DDP对肝癌细胞HepG2杀伤效应，结晶紫染色法观察细胞毒性作用；4'6-二脒基-2-苯基吲哚（DAPI）染色法检测细胞凋亡率，Western blot检测E1A蛋白的表达。实验数据比较采用单因素方差分析和LSD-t检验。

结果

SG611-EGFP感染肝癌细胞HepG2荧光显微镜下观察，随着感染复数（MOI）的增加，GFP阳性细胞数目明显增加，流式细胞术检测SG611的感染效率分别为0.18%、6.36%、50.60%、73.20%、86.80%、90.50%，呈剂量依赖性。MOI=10的SG611与1.5 μg/ml的DDP联合应用的细胞存活率为（33.2±1.2）%，明显低于单用SG611的（88.8±8.9）%（LSD-t=-7.83，P<0.05）；且联合应用对肝癌细胞HepG2的细胞毒性作用明显强于单用SG611。两者联合应用时肝癌细胞HepG2凋亡率为（23.9±1.5）%，明显高于单用SG611、DDP的（15.3±1.0）%、（12.4±1.1）%（LSD-t=10.56，21.34；P<0.05）；且联合应用时肝癌细胞HepG2的E1A表达明显增强。

结论

溶瘤腺病毒SG611联合DDP对肝癌细胞HepG2具有协同杀伤作用。SG611增加DDP化疗敏感性及DDP增强SG611增殖能力可能为其协同杀伤的作用机制。

关键词: 癌，肝细胞, 溶瘤腺病毒SG611, 顺铂, 药物协同作用, 腺病毒E1A蛋白质类

Objective

To investigate the synergistic cytotoxic effects and the mechanism of oncolytic adenovirus SG611 combined with cisplatin (DDP) on hepatocellular carcinoma (HCC) HepG2 cells.

Methods

Human HCC HepG2 cells were infected by adenovirus vector SG611 carried with green fluorescent protein (GFP). The infection efficiency of SG611 on HepG2 cells were examined by flow cytometry. The synergistic cytotoxic effects of SG611 combined with DDP on HepG2 cells were evaluated by cell counting rit(cck)-8 assay and the cytotoxicity was assessed by crystal violet staining. The 4',6-diamidino-2-phenylindole (DAPI) staining was used to detect the apoptosis. The expression of protein E1A was examined by Western blot. The comparison of experimental data was conducted using one-way analysis of variance and LSD-t test.

Results

HCC HepG2 cells infected by SG611-EGFP were observed under fluorescence microscope. The GFP positive cells increased apparently with the increasing multiplicity of infection (MOI). The infection efficiency of SG611 detected by flow cytometry was 0.18%, 6.36%, 50.60%, 73.20%, 86.80% and 90.50%, which was with dose dependent. With the combined use of SG611 (MOI =10) and 1.5 μg/ml DDP, the cell viability was (33.2±1.2)%, which was significantly lower than (88.8±8.9)% of single use of SG611 (LSD-t=-7.83, P<0.05). The cytotoxic effects on HCC HepG2 cells of combined use was significantly higher than that of single use of SG611. The apoptosis rate of HCC HepG2 cells was (23.9±1.5)% for combined use, which was significantly higher than (15.3±1.0), (12.4±1.1)% for single use of SG611 or DDP (LSD-t=10.56, 21.34; P<0.05). In addition, E1A expression in HCC HepG2 cells significantly increased when combined use.

Conclusions

Oncolytic adenovirus SG611 combined with DDP has synergistic cytotoxic effects on HCC HepG2 cells. The action mechanism of the synergistic cytotoxic effects may be that the chemosensitivity of DDP is enhanced by SG611 and the proliferation of SG611 is enhanced by DDP.

Key words: Carcinoma, hepatocellular, Oncolytic adenovirus SG611, Cisplatin, Drug synergism, Adenovirus E1A proteins

图1 溶瘤腺病毒SG611感染肝癌细胞HepG2镜下观察（荧光显微镜　×200）

图2 结晶紫染色法检测SG611联合DDP对肝癌细胞HepG2的细胞毒性作用

图3 DIPA染色检测肝癌细胞HepG2凋亡情况

图4 Western blot检测E1A蛋白表达

[1]	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, 58(2): 71-96.
[2]	Llovet JM. Updated treatment approach to hepatocellular carcinoma[J]. J Gastroenterol, 2005, 40(3): 225-235.
[3]	Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses[J]. Mol Ther, 2010, 18(2): 243-250.
[4]	Toth K, Dhar D, Wold WS. Oncolytic (replication-competent) adenoviruses as anticancer agents[J]. Expert Opin Biol Ther, 2010, 10(3): 353-368.
[5]	Guse K, Hemminki A. Cancer gene therapy with oncolytic adenoviruses[J]. J BUON, 2009, 14 Suppl 1:S7-15.
[6]	Lam JT, Bauerschmitz GJ, Kanerva A, et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids[J]. Cancer Gene Ther, 2003, 10(5): 377-387.
[7]	钱军，秦叔逵，杨爱珍，等．不同铂类药物对人肝癌细胞株抑制作用的实验研究[J]．临床肿瘤学杂志，2009, 14(5): 414-417.
[8]	Biederer C, Ries S, Brandts CH, et al. Replication-selective viruses for cancer therapy[J]. J Mol Med, 2002, 80(3): 163-175.
[9]	Zhang Q, Chen G, Peng L, et al. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus[J]. Clin Cancer Res, 2006, 12(21): 6523-6531.
[10]	Haviv YS, Blackwell JL, Kanerva A, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors[J]. Cancer Res, 2002, 62(15): 4273-4278.
[11]	Zhang J, Ramesh N, Chen Y, et al. Identification of human uroplakin Ⅱ promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel[J]. Cancer Res, 2002, 62(13): 3743-3750.
[12]	诸琦，徐凯．溶瘤病毒与胰腺癌[J]. 外科理论与实践，2007, 12(3): 295-297.
[13]	Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med, 2000, 6(8): 879-885.
[14]	Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer[J]. Clin Cancer Res, 2000, 6(3): 798-806.
[15]	Barabas K, Milner R, Lurie D, et al. Cisplatin: a review of toxicities and therapeutic applications[J]. Vet Comp Oncol, 2008, 6(1): 1-18.
[16]	Hajra KM, Tan L, Liu JR. Defective apoptosis underlies chemoresistance in ovarian cancer[J]. Adv Exp Med Biol, 2008(622): 197-208.
[17]	Wu YM, Zhang KJ, Yue XT, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24[J]. Acta Pharmacol Sin, 2009, 30(4): 467-477.
[18]	Geoerger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts[J]. Br J Cancer, 2003, 89(3): 577-584.
[19]	Shashkova EV, May SM, Barry MA. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents[J]. Virology, 2009, 394(2): 311-320.
[20]	Dilley J, Reddy S, Ko D, et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity[J]. Cancer Gene Ther, 2005, 12(8):715-722.

[1]	中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识（2024版）[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[2]	丁丁, 杨云川, 马翔, 马中正, 霍俊一, 周磊. 术前C-反应蛋白-白蛋白-淋巴细胞比值在肝细胞癌预后中的价值评估[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 261-265.
[3]	李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5]	屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6]	公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[7]	李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[8]	刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9]	焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[10]	陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[11]	袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[12]	吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13]	邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14]	王向前, 李清峰, 陈磊, 丘文丹, 姚志成, 李熠, 吴荣焕. 姜黄素抑制肝细胞癌索拉非尼耐药作用及其调控机制[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 729-735.
[15]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 407-449.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Synergistic cytotoxic effects and mechanism of oncolytic adenovirus SG611 combined with cisplatin on hepatocellular carcinoma HepG2 cells

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Synergistic cytotoxic effects and mechanism of oncolytic adenovirus SG611 combined with cisplatin on hepatocellular carcinoma HepG2 cells